BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Multiple Myeloma

May 25, 2022

Revlimid, an immunomodulatory drug (IMiD), and Velcade, a proteasome inhibitor (PI), play key roles as the backbone for combination regimens across various lines of therapy. These drugs have broad approvals in all markets, and the launch of generics in 2022 will exert substantial downward pressure on the multiple myeloma market. 

The launches of BCMA-targeted therapies will play a pivotal part in future market dynamics over the next decade. The antibody-drug conjugate (ADC) Blenrep is approved for triple-class exposed patients who have been treated with at least four prior therapies including a PI, an IMiD, and an anti-CD38 monoclonal antibody (MAb). Blenrep is also being evaluated in Phase III trials for earlier lines of therapy, with second line being a major commercial opportunity (DREAMM-7 and -8 trials). 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Multiple Myeloma (MM)
Back to the top Back to the top